Microlabs leader Dilip said, "The vaccine programme was marketed by Dolo 650. On behalf of our company, we delivered Dolo 650, masks, and sanitizer for vaccination camps. If patients developed a fever after immunisation, doctors advised them to take Dolo 650. 650 medical professionals and managers from across the country guaranteed that the Dolo 650 was distributed nationwide during the first and second waves of the Corona.
Following that, Micro Labs' research and development section focuses on pain relievers, heart illness, diabetes, eye disorders, skin diseases, and acute care. Our goal is to develop treatments for these disorders. We've learned a lot from the plague period. Incorporated a core team into the curriculum, teaching other staff how to collaborate. I was taught how to work shifts and from home.
More importantly, regardless of the data-size of the company, we looked after the financial well-being of each of our employees. In the marketing of generic pharmaceuticals, branding is quite crucial. However, the Dolo 650 was never advertised. Instead, we educated doctors about our brand and gained their trust. Our advertising consists on doctor's recommendations. We are happy as this is right now the one stop solution"